Modified Tat Peptide Carrier for PKC Cargo Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic peptides face challenges such as disulfide bond exchange, proteolytic degradation, and inefficient cellular uptake, which reduce their stability and potency.
Innovation Solution
The development of therapeutic peptide compositions that include a PKC modulatory peptide conjugated to a modified Tat peptide, which enhances plasma stability and cellular uptake by reducing disulfide bond exchange and proteolytic degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a disulfide bond is used to link carrier and cargo peptides, then cellular uptake is improved, but disulfide bond exchange occurs reducing stability
Solution Approach 1:
The patent modifies the disulfide bond environment by introducing specific amino acid sequences (such as aliphatic residues) adjacent to the cysteine residues forming the disulfide bond. This structural modification changes the chemical parameters of the disulfide bond environment, reducing its susceptibility to exchange reactions while preserving its ability to facilitate cellular uptake.
Solution Approach 2:
The patent creates a composite peptide structure where the carrier peptide and cargo peptide are linked by a disulfide bond, forming a conjugate with combined properties. The carrier peptide provides cellular uptake capability while the modified disulfide bond provides stability, creating a composite material that exhibits both functions simultaneously.
2Adaptability or versatility
If therapeutic peptides are administered systemically, then broader therapeutic coverage is achieved, but proteolytic degradation increases
Solution Approach 1:
The patent introduces specific amino acid modifications (such as N-terminal acetylation, C-terminal amidation, or incorporation of D-amino acids) that change the chemical parameters of the peptide backbone and side chains. These modifications reduce susceptibility to proteolytic enzymes while maintaining the peptide's biological activity and therapeutic function.
Solution Approach 2:
The patent employs protease-resistant peptide modifications that create a more stable, longer-lasting therapeutic agent. By protecting against degradation, the peptide maintains its therapeutic effect over extended periods, effectively replacing the need for frequent re-administration.
3Productivity
If peptide concentration is increased to improve therapeutic effect, then potency increases, but aggregation and loss of activity occur
Solution Approach 1:
The patent modifies peptide parameters such as charge distribution, hydrophobicity, and steric bulk through amino acid substitutions or additions. These parameter changes reduce intermolecular interactions that lead to aggregation, allowing higher concentrations to be achieved without loss of solubility or activity.
Solution Approach 2:
The patent introduces carrier peptides or modifying groups that act as intermediaries between the cargo peptide and the cellular environment. These intermediaries prevent direct peptide-peptide interactions that cause aggregation, while still facilitating cellular uptake and delivering the therapeutic cargo.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified therapeutic peptide compositions demonstrate increased stability and potency, with improved plasma stability and enhanced cellular uptake, leading to increased therapeutic effectiveness.
Implementation Method 1
One way to increase the potency of a therapeutic peptide comprising a carrier peptide disulfide bonded to a cargo peptide is to reduce disulfide bond exchange
Implementation Method 2
Another problem facing the use of therapeutic peptides is proteolytic degradation
Data Source
AI summary
The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake.